| Medical and Health Sciences | Lifetime | 721 | IN 3 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 311 | IN 3 | 99.94 |
| Epidemiology | Lifetime | 89 | IN 1 | 99.87 |
| Hepatology | Lifetime | 18 | IN 1 | 99.85 |
| Surgery | Lifetime | 816 | IN 3 | 99.23 |
| Pathology and Forensic Medicine | Lifetime | 615 | IN 1 | 97.21 |
| Pharmacology | Lifetime | 521 | IN 13 | 94.06 |
| Gastroenterology | Lifetime | 510 | IN 7 | 89.26 |
| Epidemiology | 2021-2025 | 46 | IN 1 | 99.77 |
| Hepatology | 2021-2025 | 15 | IN 1 | 99.69 |
| Surgery | 2021-2025 | 443 | IN 6 | 96.52 |
| Pathology and Forensic Medicine | 2021-2025 | 213 | IN 1 | 93.86 |
| Pharmacology | 2021-2025 | 78 | IN 7 | 91.17 |
| Infectious Diseases | 2021-2025 | 870 | IN 18 | 76.55 |
| Liver Disease and Transplantation | Lifetime | 17 | IN 1 | 99.90 |
| Liver Disease Diagnosis and Treatment | Lifetime | 51 | IN 1 | 99.88 |
| Organ Transplantation Techniques and Outcomes | Lifetime | 36 | IN 1 | 99.80 |
| Hepatitis B Virus Studies | Lifetime | 59 | IN 1 | 99.77 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 26 | IN 2 | 99.67 |
| Hepatitis C virus research | Lifetime | 88 | IN 1 | 99.67 |
| Hepatitis Viruses Studies and Epidemiology | Lifetime | 26 | IN 2 | 99.56 |
| Abdominal vascular conditions and treatments | Lifetime | 32 | IN 1 | 98.82 |
| Alcohol Consumption and Health Effects | Lifetime | 86 | IN 1 | 98.92 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 372 | IN 1 | 98.75 |
| Gastrointestinal Bleeding Diagnosis and Treatment | Lifetime | 91 | IN 1 | 98.00 |
| Pancreatitis Pathology and Treatment | Lifetime | 552 | IN 9 | 97.64 |
| Systemic Sclerosis and Related Diseases | Lifetime | 322 | IN 1 | 97.51 |
| Liver Diseases and Immunity | Lifetime | 345 | IN 2 | 97.32 |
| Gallbladder and Bile Duct Disorders | Lifetime | 837 | IN 13 | 97.05 |
| Liver physiology and pathology | Lifetime | 669 | IN 4 | 95.33 |
| Acute Kidney Injury Research | Lifetime | 834 | IN 11 | 93.16 |
| Biliary and Gastrointestinal Fistulas | Lifetime | 899 | IN 31 | 89.71 |
| Amoebic Infections and Treatments | Lifetime | 953 | IN 43 | 87.87 |
| Drug-Induced Hepatotoxicity and Protection | 2021-2025 | 2 | IN 1 | 99.41 |
| Liver Disease and Transplantation | 2021-2025 | 7 | IN 1 | 99.84 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 40 | IN 1 | 99.77 |
| Organ Transplantation Techniques and Outcomes | 2021-2025 | 11 | IN 2 | 99.44 |
| Alcohol Consumption and Health Effects | 2021-2025 | 29 | IN 1 | 98.37 |
| Hepatitis C virus research | 2021-2025 | 134 | IN 2 | 97.48 |
| Hepatitis B Virus Studies | 2021-2025 | 219 | IN 1 | 96.02 |
| Diet, Metabolism, and Disease | 2021-2025 | 234 | IN 6 | 93.46 |
| Hepatitis Viruses Studies and Epidemiology | 2021-2025 | 135 | IN 5 | 90.29 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 736 | IN 9 | 90.30 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 959 | IN 6 | 91.20 |
| Abdominal vascular conditions and treatments | 2021-2025 | 80 | IN 4 | 84.11 |
| Acute Kidney Injury Research | 2021-2025 | 579 | IN 12 | 82.33 |
| Clinical Nutrition and Gastroenterology | 2021-2025 | 451 | IN 2 | 81.86 |
| Liver Diseases and Immunity | 2021-2025 | 848 | IN 11 | 77.85 |
| Gastrointestinal Bleeding Diagnosis and Treatment | 2021-2025 | 530 | IN 24 | 73.80 |
| Electrolyte and hormonal disorders | 2021-2025 | 616 | IN 6 | 67.85 |
| Renal function and acid-base balance | 2021-2025 | 494 | IN 6 | 63.41 |
| Hydrogen's biological and therapeutic effects | 2021-2025 | 816 | IN 16 | 16.78 |
